AU2003300113B2 - Topical stabilized prostaglandin E compound dosage forms - Google Patents

Topical stabilized prostaglandin E compound dosage forms Download PDF

Info

Publication number
AU2003300113B2
AU2003300113B2 AU2003300113A AU2003300113A AU2003300113B2 AU 2003300113 B2 AU2003300113 B2 AU 2003300113B2 AU 2003300113 A AU2003300113 A AU 2003300113A AU 2003300113 A AU2003300113 A AU 2003300113A AU 2003300113 B2 AU2003300113 B2 AU 2003300113B2
Authority
AU
Australia
Prior art keywords
parts
weight
prostaglandin
dimethylamino
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003300113A
Other languages
English (en)
Other versions
AU2003300113A1 (en
Inventor
Daniel W. Frank
Y. Joseph Mo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring International Center SA
Original Assignee
Ferring International Center SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring International Center SA filed Critical Ferring International Center SA
Publication of AU2003300113A1 publication Critical patent/AU2003300113A1/en
Application granted granted Critical
Publication of AU2003300113B2 publication Critical patent/AU2003300113B2/en
Assigned to FERRING INTERNATIONAL CENTER S.A. reassignment FERRING INTERNATIONAL CENTER S.A. Request for Assignment Assignors: NEXMED HOLDINGS, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2003300113A 2003-01-03 2003-12-31 Topical stabilized prostaglandin E compound dosage forms Expired AU2003300113B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/336,481 2003-01-03
US10/336,481 US6841574B2 (en) 2003-01-03 2003-01-03 Topical stabilized prostaglandin E compound dosage forms
PCT/US2003/041658 WO2004062632A1 (en) 2003-01-03 2003-12-31 Topical stabilized prostaglandin e compound dosage forms

Publications (2)

Publication Number Publication Date
AU2003300113A1 AU2003300113A1 (en) 2004-08-10
AU2003300113B2 true AU2003300113B2 (en) 2010-03-11

Family

ID=32681022

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003300113A Expired AU2003300113B2 (en) 2003-01-03 2003-12-31 Topical stabilized prostaglandin E compound dosage forms

Country Status (16)

Country Link
US (1) US6841574B2 (cg-RX-API-DMAC7.html)
EP (1) EP1585483B1 (cg-RX-API-DMAC7.html)
JP (2) JP2006514068A (cg-RX-API-DMAC7.html)
KR (2) KR101174788B1 (cg-RX-API-DMAC7.html)
CN (1) CN100574763C (cg-RX-API-DMAC7.html)
AT (1) ATE468098T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003300113B2 (cg-RX-API-DMAC7.html)
BR (1) BR0317924A (cg-RX-API-DMAC7.html)
CA (1) CA2512015C (cg-RX-API-DMAC7.html)
DE (1) DE60332656D1 (cg-RX-API-DMAC7.html)
DK (1) DK1585483T3 (cg-RX-API-DMAC7.html)
ES (1) ES2343246T3 (cg-RX-API-DMAC7.html)
IL (1) IL169425A (cg-RX-API-DMAC7.html)
PT (1) PT1585483E (cg-RX-API-DMAC7.html)
WO (1) WO2004062632A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200505321B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
KR101086147B1 (ko) 2003-03-21 2011-11-25 넥스메드 홀딩스 인코포레이티드 조루증 치료용 조성물 및 치료 방법
US20050113274A1 (en) * 2003-11-22 2005-05-26 Nadir Buyuktimkin Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
WO2006133048A2 (en) * 2005-06-03 2006-12-14 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
ITMI20051417A1 (it) * 2005-07-22 2007-01-23 Mipharm S P A Formulazione topica in forma di gel contenente come ingredienti attivi ciclovit e lidocaina
AU2006322050A1 (en) * 2005-12-06 2007-06-14 Monosol Rx, Llc Topical film compositions for delivery of actives
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) * 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
WO2012139033A1 (en) 2011-04-07 2012-10-11 Nexmed Holdings, Inc. Methods and compositions for treating raynaud's disease
CA2848397C (en) 2011-09-14 2022-04-26 Forsight Vision5, Inc. Ocular insert apparatus and methods
WO2014066775A1 (en) 2012-10-26 2014-05-01 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US8900625B2 (en) * 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
WO2019142015A1 (es) * 2018-01-18 2019-07-25 Caicedo Pinto, David Felipe Composicion farmaceutica para la disfuncion erectil de administracion transdermica via uretral en gotas

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4594240A (en) * 1982-09-10 1986-06-10 Teikoku Seiyaku Kabushiki Kaisha Sheet-shape adhesive preparation
US4818517A (en) * 1986-01-24 1989-04-04 Akzo N.V. Pharmaceutical preparation for obtaining a highly viscose hydrogel or suspension
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
WO1999066870A1 (en) * 1998-06-25 1999-12-29 Lavipharm Laboratories, Inc. A device and method for the treatment of erectile dysfunction
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US20010044467A1 (en) * 1997-10-20 2001-11-22 Neal Gary W. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883576A (en) * 1971-02-02 1975-05-13 Upjohn Co Prostaglandin E{HD 3 {B analogs
US3826823A (en) * 1972-09-25 1974-07-30 Syntex Inc Stabilized prostaglandin preparations
US3875300A (en) * 1972-12-18 1975-04-01 Ortho Pharma Corp Composition for sustained release of a medicament and method of using same
US5017382A (en) * 1979-03-21 1991-05-21 National Research Development Corporation Controlled release compositions (II)
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
JPS58134019A (ja) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
JPS6185315A (ja) * 1984-10-04 1986-04-30 Teikoku Seiyaku Kk シ−ト状製剤
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
SE9501670L (sv) * 1995-05-05 1996-06-10 Perstorp Ab Omläggningsset
US20020004529A1 (en) * 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
KR100402334B1 (ko) * 2000-06-23 2003-10-22 환인제약 주식회사 알프로스타딜 외용제

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4594240A (en) * 1982-09-10 1986-06-10 Teikoku Seiyaku Kabushiki Kaisha Sheet-shape adhesive preparation
US4818517A (en) * 1986-01-24 1989-04-04 Akzo N.V. Pharmaceutical preparation for obtaining a highly viscose hydrogel or suspension
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
US20010044467A1 (en) * 1997-10-20 2001-11-22 Neal Gary W. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
WO1999066870A1 (en) * 1998-06-25 1999-12-29 Lavipharm Laboratories, Inc. A device and method for the treatment of erectile dysfunction
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction

Also Published As

Publication number Publication date
CN100574763C (zh) 2009-12-30
CN1756532A (zh) 2006-04-05
PT1585483E (pt) 2010-06-17
US20040131664A1 (en) 2004-07-08
ATE468098T1 (de) 2010-06-15
JP2006514068A (ja) 2006-04-27
EP1585483A4 (en) 2006-04-19
US6841574B2 (en) 2005-01-11
CA2512015A1 (en) 2004-07-29
WO2004062632A1 (en) 2004-07-29
JP5395138B2 (ja) 2014-01-22
JP2012036196A (ja) 2012-02-23
AU2003300113A1 (en) 2004-08-10
KR20050098853A (ko) 2005-10-12
EP1585483B1 (en) 2010-05-19
BR0317924A (pt) 2005-11-29
KR101174788B1 (ko) 2012-08-20
HK1090293A1 (zh) 2006-12-22
EP1585483A1 (en) 2005-10-19
CA2512015C (en) 2011-11-08
DE60332656D1 (de) 2010-07-01
ES2343246T3 (es) 2010-07-27
IL169425A (en) 2010-11-30
ZA200505321B (en) 2006-04-26
DK1585483T3 (da) 2010-07-19
KR20110042138A (ko) 2011-04-22

Similar Documents

Publication Publication Date Title
JP5395138B2 (ja) 局所安定化プロスタグランジンe化合物剤形
US6046244A (en) Topical compositions for prostaglandin E1 delivery
JP2014055144A (ja) 局所安定化プロスタグランジンe化合物剤形
AU2007307136B2 (en) Stabilized prostaglandin E composition
HK1090293B (en) Topical stabilized prostaglandin e compound dosage forms
AU2014201174B2 (en) Stabilized prostaglandin e composition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: FERRING INTERNATIONAL CENTER S.A.

Free format text: FORMER OWNER(S): NEXMED HOLDINGS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired